FDA
-
-
-
-
-
-
-
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference
-
-
-
-
-
-
-
BioDelivery Sciences (BDSI) Sees Q4 Total Net Sales at High End of Guidance
-
-
-
-
-
-
-
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
-
-
-
-
-
-
-
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
-
-
-
-
-
-
-
CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
BioDelivery Sciences (BDSI) Settles Patent Litigation with Teva (TEVA)
-
-
-
-
-
-
-
Cantor Fitzgerald Assumes BioDelivery Sciences International (BDSI) at Overweight
-
322,091 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

